DIAGNOSIS AND TREATMENT OF PATIENTS WITH SECONDARY HYPERPARATHYROIDISM AND RENAL INSUFFICIENCY. THERAPEUTIC POTENTIAL OF PARICALCITOL

Медицинский совет

Zh. E. Belaya¹  L. Ya. Rozhinskaya¹ 

[1] National Medical Research Center of Endocrinology of the Ministry of Health of Russia.;

关键词: secondary hyperparathyroidism;    renal failure;    paricalcitol;   

DOI  :  10.21518/2079-701X-2017-20-151-156

来源: DOAJ

【 摘 要 】

A review of the literature is devoted to the issue of secondary hyperparathyroidism (SHPT) with underlying chronic renal failure. Initial manifestations of the disease can be observed even with a minimal decrease in the rate of glomerular filtration and are pathophysiologically associated with violations of normal metabolism of vitamin D with its conversion into D-hormone. SHPT pathogenesis is based on the D-hormone deprivation and triggering of pathophysiology mechanisms of bone remodelling, increased FRP-23, PTH, changes in the serum levels of calcium and phosphorus, which may further lead to significant changes in the bone tissue structure and cardiovascular complications. Active metabolites of vitamin D and vitamin D analogues (Paricalcitol) were developed for the replacement of active forms of vitamin D in conditions of D-hormone deficiency. Due to its chemical structure and pharmacokinetics, Paricalcitol is able to block the synthesis of parathyroid hormone to a greater extent and increase the absorption of calcium and phosphorus in the intestine to a lesser extent, which gives it advantages over pre-existing active metabolites

【 授权许可】

Unknown